期刊
INTERNATIONAL JOURNAL OF CARDIOLOGY
卷 275, 期 -, 页码 77-82出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2018.10.024
关键词
Atrial fibrillation; Ankylosing spondylitis
资金
- Seoul National University Hospital Research Fund [062018245]
- Korea National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2014R1A1A2A16055218]
- Technology Innovation Program or Industrial Strategic Technology Development Program - Ministry of Trade, Industry and Energy (MOTIE, Sejong, Korea) [10052668]
Background: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease, associated with a number of cardiovascular diseases. We sought to investigate whether AS increases the risk of atrial fibrillation (AF) in a nationwide population-based study. Methods: A total of 14,129 patients newly diagnosed with AS (mean age 41.8 +/- 15.3 years, 72% male) were recruited from the Korean National Health Insurance Service database between 2010 and 2014 and followed up for new onset AF. Age-and sex-matched non-AS subjects (1: 5, n = 70,645) were selected and compared with the AS patients. Results: During a mean follow-up of 3.5 years, AF was newly diagnosed in 486 patients (114 patients of the AS group). The AS patients developed AF more frequently than the non-AS subjects (2.32 vs. 1.51 per 1000 person-years). In multivariate Cox regression analysis, AS was an independent risk factor for AF (Hazard ratio [HR] 1.28, 95% confidence interval [1.03-1.58]). The AS with tumor necrosis factor inhibitor (TNFi) therapy group showed higher risk for AF (HR 1.60 [1.02-2.39]). In younger patients of the AS group (patients <40 years old), the risk for AF was three times higher than patients at same age in the non-AS group. AS was an independent risk factor for AF in men, but not in women (HR 1.53 [1.18-1.95]; HR 1.42 [0.94-2.08], respectively). Conclusions: AS was an independent risk factor for AF, especially in those under 40 years of age and those administered TNFi. It would be reasonable to screen for AF and stroke prevention in these high-risk patients. (c) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据